Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.44 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.44 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.44 |
| ▸ | FNTA | P49354 | 5/20 | 0.42 |
| ▸ | FNTB | P49356 | 5/20 | 0.42 |
| ▸ | PGGT1B | P53609 | 4/20 | 0.42 |
| ▸ | LTA4H | P09960 | 2/20 | 0.42 |
| ▸ | TACR3 | P29371 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1128048 | 0.89 | ANPEP (0.50) | ANPEPRNPEPDNPEPFNTAFNTB | |
| SCHEMBL61200 | 0.89 | ANPEP (0.43) | ANPEPRNPEPDNPEPFNTAFNTB | |
| Acetic Acid SCHEMBL15201184 | 0.87 | ANPEP (0.48) | ANPEPRNPEPDNPEPFNTAFNTB | |
| SCHEMBL1695338 | 0.81 | FOLH1 (0.39) | ANPEPRNPEPDNPEPFNTAFNTB | |
| SCHEMBL27468737 | 0.77 | ANPEP (0.53) | ANPEPRNPEPDNPEPLTA4H | |
| SCHEMBL7999637 | 0.77 | ANPEP (0.51) | ANPEPRNPEPDNPEPLTA4H | |
| SCHEMBL28194148 | 0.77 | ANPEP (0.42) | ANPEPRNPEPDNPEPFNTAFNTB | |
| SCHEMBL9242775 | 0.76 | ANPEP (0.43) | ANPEPRNPEPDNPEPLTA4H | |
| SCHEMBL19974077 | 0.75 | ANPEP (0.51) | ANPEPRNPEPDNPEPLTA4H | |
| SCHEMBL39530 | 0.74 | ANPEP (0.37) | ANPEPRNPEPDNPEPFNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865857-B2 | Medical device with predefined activated cellular integration | SOFRADIM PRODUCTION (FR) | 2014-10-21 | — | — | US | claimed |
| US-4732155-A | Implantable chemoattractant system | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1988-03-22 | — | — | US | claimed |
| US-8865857-B2 | Medical device with predefined activated cellular integration | SOFRADIM PRODUCTION (FR) | 2014-10-21 | — | — | US | disclosed |
| US-20130143976-A1 | MEDICAL DEVICE WITH PREDEFINED ACTIVATED CELLULAR INTEGRATION | SOFRADIM PRODUCTION (FR) | 2013-06-06 | — | — | US | disclosed |
| EP-2588153-A2 | MEDICAL DEVICE WITH PREDEFINED ACTIVATED CELLULAR INTEGRATION | Sofradim Production (FR) | 2013-05-08 | — | — | EP | disclosed |
| WO-2012001532-A2 | MEDICAL DEVICE WITH PREDEFINED ACTIVATED CELLULAR INTEGRATION | SOFRADIM PRODUCTION (FR) | 2012-01-05 | — | — | WO | disclosed |
| US-20030138432-A1 | Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs | DRUG INNOVATION & DESIGN, INC. | 2003-07-24 | — | — | US | disclosed |
| EP-1255567-A1 | SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES | Drug Innovation & Design, Inc. (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001036003-A2 | SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES | DRUG INNOVATION & DESIGN, INC. (US) | 2001-05-25 | — | — | WO | disclosed |
| US-4732155-A | Implantable chemoattractant system | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1988-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143976-A1 | MEDICAL DEVICE WITH PREDEFINED ACTIVATED CELLULAR INTEGRATION | CCL2, MIF, C3AR1 | ANPEP 741/4885RNPEP 904/4885DNPEP 656/4885 |
| US-20030138432-A1 | Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs | PAICS, ABCB1, ABCG2 | ANPEP 1636/4885RNPEP 1962/4885DNPEP 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.